Rhenman & Partners Asset Management Ab Karuna Therapeutics, Inc. Transaction History

Rhenman & Partners Asset Management Ab

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 13, 2023	SELL	$164.66 - $218.08 $42.3 Million - $56 Million	-257,000 Reduced 88.01%	35,000 $5.92 Million
Q3 2023 Nov 09, 2023	BUY	$164.66 - $218.08 $42.3 Million - $56 Million	257,000 Added 734.29%	292,000 $49.4 Million
Q2 2023 Aug 11, 2023	SELL	$176.32 - $240.22 $352,640 - $480,440	-2,000 Reduced 5.41%	35,000 $7.59 Million
Q1 2023 May 11, 2023	BUY	$161.33 - $204.36 $1.13 Million - $1.43 Million	7,000 Added 23.33%	37,000 $6.72 Million
Q4 2022 Feb 13, 2023	BUY	$191.53 - $236.82 $1.92 Million - $2.37 Million	10,000 Added 50.0%	30,000 $5.9 Million
Q3 2022 Nov 14, 2022	BUY	$123.79 - $277.42 $2.48 Million - $5.55 Million	20,000 New	20,000 $4.39 Million

332K

Ticker KRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 33,965,000
Description
Karuna Therapeutics, Inc., a clinical-stage biopharmaceutical company, creates and delivers transformative medicines for people living with psychiatric and neurological conditions. Its lead product candidate is KarXT, an oral modulator of muscarinic receptors that is in Phase III clinical trial for the treatment of acute psychosis in patients wi...

Get notified when there are updates to the investment portfolio of Rhenman & Partners Asset Management Ab, based on Form 13F filings with the SEC.

Stay updated on Rhenman & Partners Asset Management Ab with notifications on news.